Our work describes pro-tumorigenic marker proteins that identify tumor-supportive mononuclear cells and establishes a basis for therapeutic intervention aimed at neutralising these STAT3 and EGFR activators at the molecular level. This evidence concerns the gene EGFR and neoplasm.